Who is funding R&D for emerging infectious diseases? Dr Paul Barnsley, Policy Cures Research

Published: July 21, 2022, 1 a.m.

b'

Last month at the Global Health Security Conference in Singapore, Policy Cures Research launched their second edition of the Landscape of Emerging Infectious Disease Research and Development funding report, supported by the Australian Government.\\xa0

Our guest this week is Dr Paul Barnsley, Senior Analyst at Policy Cures Research, and the lead author of the report, who joins us to talk about its key findings.\\xa0

We discuss how R&D funding for Ebola ultimately led to success in creating a stable of products that limits its risk of its pandemic potential. Plus, how the unprecedented R&D response to the Covid-19 pandemic is reshaped the funding landscape for emerging infectious disease R&D into the future.\\xa0

Dr Barnsley also speaks about the promising new entrants in EID R&D funding from low to middle income countries, given that they are often the countries that epidemic disease does most harm. \\xa0

We hope you join the conversation at @CentreHealthSec and follow Policy Cures Research at @PCuresResearch.\\xa0

'